Financial
-
Johnson & Johnson to Acquire Shockwave Medical
Enhances Johnson & Johnson’s Ability to Transform the Treatment Landscape for Cardiovascular Disease and Continue to Improve Patient Outcomes Extends Johnson & Johnson MedTech’s Position in Highest-Growth, Innovation-Oriented Segments of Cardiovascular Intervention Accelerates Sales Growth and Accretive to Operating Margin for Both Johnson & Johnson and Johnson & Johnson MedTech Conference Call at 8:30 a.m. ET To Discuss Details of the Transaction -
-
-
-
-
-
-
-
Johnson & Johnson Reports Q4 and Full-Year 2023 Results
Johnson & Johnson (NYSE: JNJ) today announced results for fourth-quarter and full year 2023.